The company is on a growth path due to increased incidence of colorectal cancer. Add to this, a windfall from a competitor winding down and revenue growth is accelerating and will accelerate more in H2 and next year. This will produce operational leverage and next year a substantial reduction in CapEx, so profit growth is […]
Entries Tagged as 'INFU'
September 6th, 2019 · No Comments